Invention Grant
- Patent Title: Bridged and fused antidiabetic compounds
- Patent Title (中): 桥接和融合的抗糖尿病化合物
-
Application No.: US14044316Application Date: 2013-10-02
-
Publication No.: US09278965B2Publication Date: 2016-03-08
- Inventor: Hubert B. Josien , John W. Clader , William J. Greenlee , Michael J. Mayer , Jason L. Davis , Shuangyi Wan
- Applicant: Merck Sharp & Dohme Corp.
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent Anna L. Cocuzzo; Catherine D. Fitch
- Main IPC: C07D417/14
- IPC: C07D417/14 ; C07D263/44 ; C07D277/34 ; C07D417/04 ; C07D417/12

Abstract:
This invention provides for certain bridged and fused compounds of the formula G-L-A I or a pharmaceutically acceptable salt, ester of solvate thereof wherein: A is and the other variables are defined herein; the inventive compounds are agonists of the G-protein coupled receptor 40 (GPR40, also known as free fatty acid receptor FFAR). This invention further relates to pharmaceutical compositions containing these compounds, and the use of these compounds to regulate insulin levels in a mammal. The compounds may be used, for example in the prevention and treatment of Type 2 diabetes mellitus and in the prevention and treatment of conditions related to Type 2 diabetes mellitus, such as insulin resistance, obesity and lipid disorders.
Public/Granted literature
- US20140038970A1 BRIDGED AND FUSED ANTIDIABETIC COMPOUNDS Public/Granted day:2014-02-06
Information query